WO2008029152A3 - Treatment of duchenne muscular dystrophy - Google Patents

Treatment of duchenne muscular dystrophy Download PDF

Info

Publication number
WO2008029152A3
WO2008029152A3 PCT/GB2007/003377 GB2007003377W WO2008029152A3 WO 2008029152 A3 WO2008029152 A3 WO 2008029152A3 GB 2007003377 W GB2007003377 W GB 2007003377W WO 2008029152 A3 WO2008029152 A3 WO 2008029152A3
Authority
WO
WIPO (PCT)
Prior art keywords
muscular dystrophy
different
same
duchenne muscular
treatment
Prior art date
Application number
PCT/GB2007/003377
Other languages
French (fr)
Other versions
WO2008029152A2 (en
Inventor
Graham Michael L Wynne
Stephen Paul Wren
Cristina Lecci
Original Assignee
Summit Corp Plc
Graham Michael L Wynne
Stephen Paul Wren
Cristina Lecci
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0617739A external-priority patent/GB0617739D0/en
Priority claimed from GB0619282A external-priority patent/GB0619282D0/en
Priority claimed from GB0623985A external-priority patent/GB0623985D0/en
Application filed by Summit Corp Plc, Graham Michael L Wynne, Stephen Paul Wren, Cristina Lecci filed Critical Summit Corp Plc
Publication of WO2008029152A2 publication Critical patent/WO2008029152A2/en
Publication of WO2008029152A3 publication Critical patent/WO2008029152A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

There are disclosed compounds of formula I, wherein A1, A2, A3, A4 and A5 which may be the same or different, represent N or CR1 Y and Z, which may be the same or different, represent O, S(O)n, C=W, NR4, NC(=O)R5 and CR6R7, W is O, S, NR20, one of R4, R5, R6, and R20 represents - L - R3, in which L is a single bond or a linker group, additionally, R3, R 4, R 5, R6, and R7, which may be the same or different, independently represent hydrogen or a substituent-or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the therapeutic arid/or prophylactic treatment of Duchenne muscular dystrophy, Becker muscular dystrophy or cachexia.
PCT/GB2007/003377 2006-09-08 2007-09-07 Treatment of duchenne muscular dystrophy WO2008029152A2 (en)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
GB0617739.8 2006-09-08
GB0617739A GB0617739D0 (en) 2006-09-08 2006-09-08 Treatment of duchenne muscular dystrophy
GB0619282.7 2006-09-29
GB0619282A GB0619282D0 (en) 2006-09-29 2006-09-29 Treatment of duchenne muscular dystrophy
GB0623985.9 2006-11-30
GB0623985A GB0623985D0 (en) 2006-11-30 2006-11-30 Treatment of duchenne muscular dystrophy

Publications (2)

Publication Number Publication Date
WO2008029152A2 WO2008029152A2 (en) 2008-03-13
WO2008029152A3 true WO2008029152A3 (en) 2008-05-08

Family

ID=38947387

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2007/003377 WO2008029152A2 (en) 2006-09-08 2007-09-07 Treatment of duchenne muscular dystrophy

Country Status (1)

Country Link
WO (1) WO2008029152A2 (en)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8563573B2 (en) 2007-11-02 2013-10-22 Vertex Pharmaceuticals Incorporated Azaindole derivatives as CFTR modulators
EP2096923B1 (en) 2006-11-27 2014-01-22 H. Lundbeck A/S Heteroaryl amide derivatives
EP1964840A1 (en) * 2007-02-28 2008-09-03 sanofi-aventis Imidazo[1,2-a]pyridines and their use as pharmaceuticals
GB0715938D0 (en) * 2007-08-15 2007-09-26 Vastox Plc Method of treatment of duchenne muscular dystrophy
US8067409B2 (en) 2007-11-27 2011-11-29 Abbott Laboratories Protein kinase inhibitors
DK2280706T3 (en) 2008-05-14 2013-02-04 Otsuka Pharma Co Ltd Lipasa activating lipoprotein compositions comprising benzene derivatives
GB0809314D0 (en) * 2008-05-22 2008-07-02 Summit Corp Plc Compounds for treating muscular dystrophy
EP2338059B1 (en) * 2008-09-23 2015-04-08 WisTa Laboratories Ltd. Ligands for aggregated tau molecules
TWI491610B (en) 2008-10-09 2015-07-11 必治妥美雅史谷比公司 Imidazopyridazinecarbonitriles useful as kinase inhibitors
GB0822981D0 (en) * 2008-12-17 2009-01-21 Summit Corp Plc Compounds for treatment of duchenne muscular dystrophy
WO2010086040A1 (en) * 2009-01-29 2010-08-05 Biomarin Iga, Ltd. Pyrazolo-pyrimidines for treatment of duchenne muscular dystrophy
EP2427463A1 (en) * 2009-05-05 2012-03-14 Limited Liability Company "Innovative Pharma" Imidazo [1, 2 -a] pyridin-2 -yl-phenyl derivatives to be used in cancer treatment
EP2480531B1 (en) 2009-09-21 2014-11-05 ChemoCentryx, Inc. Pyrrolidinone carboxamide derivatives as chemerin-r (chemr23) modulators
US8802868B2 (en) 2010-03-25 2014-08-12 Vertex Pharmaceuticals Incorporated Solid forms of (R)-1(2,2-difluorobenzo[D][1,3]dioxo1-5-yl)-N-(1-(2,3-dihydroxypropyl-6-fluoro-2-(1-hydroxy-2-methylpropan2-yl)-1H-Indol-5-yl)-Cyclopropanecarboxamide
KR101984225B1 (en) 2010-04-22 2019-05-30 버텍스 파마슈티칼스 인코포레이티드 Process of producing cycloalkylcarboxamido-indole compounds
TWI617559B (en) * 2010-12-22 2018-03-11 江蘇恆瑞醫藥股份有限公司 2-arylimidazo[1,2-b]pyridazine, 2-phenylimidazo[1,2-a]pyridine, and 2-phenylimidazo[1,2-a]pyrazine derivatives
EP2694500B1 (en) 2011-04-06 2015-05-27 Bayer Pharma Aktiengesellschaft Substituted imidazopyridines and intermediates thereof
WO2014103801A1 (en) 2012-12-28 2014-07-03 株式会社新日本科学 Oct3 activity inhibitor containing imidazopyridine derivative as active component, and oct3 detection agent
ES2616026T3 (en) 2013-03-11 2017-06-09 Bristol-Myers Squibb Company Pyrrolopyridazines as potassium ion channel inhibitors
PT3925607T (en) 2014-04-15 2023-09-26 Vertex Pharma Pharmaceutical compositions for the treatment of cystic fibrosis transmembrane conductance regulator mediated diseases
MY187540A (en) 2014-08-01 2021-09-28 Nuevolution As Compounds active towards bromodomains
WO2016148114A1 (en) * 2015-03-13 2016-09-22 国立大学法人北海道大学 Compound capable of inhibiting oxidative stress-induced neuronal cell death
WO2021240187A1 (en) * 2020-05-29 2021-12-02 Semmelweis Egyetem Benzamide derivatives as anti-inflammatory compounds and uses thereof
EP4265248A1 (en) * 2022-04-22 2023-10-25 Université Paris Cité Compounds inducing production of proteins by immune cells

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991000092A1 (en) * 1989-06-13 1991-01-10 Smithkline Beecham Corporation Inhibition of interleukin-1 and tumor necrosis factor production by monocytes and/or macrophages
WO2004050076A1 (en) * 2002-11-28 2004-06-17 Centre National De La Recherche Scientifique Cnrs Use of a histone deacetylase inhibitor for treating muscular dystrophies
WO2005092899A1 (en) * 2004-03-26 2005-10-06 Methylgene Inc. Inhibitors of histone deacetylase
WO2005105798A1 (en) * 2004-04-30 2005-11-10 Grünenthal GmbH Substituted imidazo[1,2-a]pyridine compounds and drugs containing substituted imidazo[1,2-a]pyridine compounds
US20050288502A1 (en) * 2004-06-25 2005-12-29 Andersen Denise L Substituted heterocyclic compounds and methods of use
WO2006007910A1 (en) * 2004-07-20 2006-01-26 Santhera Pharmaceuticals (Schweiz) Ag Use of non-glucocorticoid steroids for the treatment of muscular dystrophy
WO2006094235A1 (en) * 2005-03-03 2006-09-08 Sirtris Pharmaceuticals, Inc. Fused heterocyclic compounds and their use as sirtuin modulators
WO2006094236A1 (en) * 2005-03-03 2006-09-08 Sirtris Pharmaceuticals, Inc. N-phenyl benzamide derivatives as sirtuin modulators
WO2006101455A1 (en) * 2005-03-21 2006-09-28 S*Bio Pte Ltd Imidazo[1,2-a]pyridine derivatives: preparation and pharmaceutical applications

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991000092A1 (en) * 1989-06-13 1991-01-10 Smithkline Beecham Corporation Inhibition of interleukin-1 and tumor necrosis factor production by monocytes and/or macrophages
WO2004050076A1 (en) * 2002-11-28 2004-06-17 Centre National De La Recherche Scientifique Cnrs Use of a histone deacetylase inhibitor for treating muscular dystrophies
WO2005092899A1 (en) * 2004-03-26 2005-10-06 Methylgene Inc. Inhibitors of histone deacetylase
WO2005105798A1 (en) * 2004-04-30 2005-11-10 Grünenthal GmbH Substituted imidazo[1,2-a]pyridine compounds and drugs containing substituted imidazo[1,2-a]pyridine compounds
US20050288502A1 (en) * 2004-06-25 2005-12-29 Andersen Denise L Substituted heterocyclic compounds and methods of use
WO2006007910A1 (en) * 2004-07-20 2006-01-26 Santhera Pharmaceuticals (Schweiz) Ag Use of non-glucocorticoid steroids for the treatment of muscular dystrophy
WO2006094235A1 (en) * 2005-03-03 2006-09-08 Sirtris Pharmaceuticals, Inc. Fused heterocyclic compounds and their use as sirtuin modulators
WO2006094236A1 (en) * 2005-03-03 2006-09-08 Sirtris Pharmaceuticals, Inc. N-phenyl benzamide derivatives as sirtuin modulators
WO2006101455A1 (en) * 2005-03-21 2006-09-28 S*Bio Pte Ltd Imidazo[1,2-a]pyridine derivatives: preparation and pharmaceutical applications

Also Published As

Publication number Publication date
WO2008029152A2 (en) 2008-03-13

Similar Documents

Publication Publication Date Title
WO2008029152A3 (en) Treatment of duchenne muscular dystrophy
WO2008029168A3 (en) Treatment of duchenne muscular dystrophy
WO2008142055A3 (en) Antiviral agents
WO2007091106A3 (en) Treatment of duchenne muscular dystrophy
MX2009006742A (en) Novel compounds.
MY145647A (en) (4-hydroxy-2-oxo-3h-benzothiazol-7-yl)ethylamine derivatives, processes for their preparation, pharmaceutical compositions containing them and their use in therapy (for example in the treatment of respiratory disease states)
MX2009012558A (en) Drug combinations for the treatment of duchenne muscular dystrophy.
MY127126A (en) Imidazolo-5-yl-2-anilino-pyrimidines as agents for the inhibition of the cell proliferation
EP2041159B8 (en) Macrocyclic compounds as antiviral agents
MX2009003157A (en) Therapeutic pyrazolyl thienopyridines.
TW200602328A (en) Quinazoline derivatives
TW200621762A (en) Novel compounds
IL182315A0 (en) 3-ether and 3-thioether substituted cyclosporin derivatives for the treatment and prevention of hepatitis c infection
WO2005111002A3 (en) Substituted cycloalkyl derivatives for use in the treatment of respiratory diseases
MY145133A (en) Aryl-substituted polycyclic amines, process for their preparation and their use as medicaments
GB0413087D0 (en) Therapeutic compounds
SG170069A1 (en) Quinoline derivatives
EP2039686A4 (en) Dihydropyrimidine compounds and their uses in preparation of medicaments for treating and preventing antiviral diseases
MX2010008921A (en) Oxazolidinone derivatives.
TW200800969A (en) Compounds
WO2008147557A3 (en) Heteroaryl substituted thiazoles and their use as antiviral agents
WO2008069917A3 (en) Novel cyclic peptides
MX2009008756A (en) Macrocyclic compound.
GEP20135883B (en) Iminopyridine derivatives and usage thereof
TW200716547A (en) Piperidin-4-yl-amide derivatives

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07804177

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 07804177

Country of ref document: EP

Kind code of ref document: A2